Xlife Sciences AG (XLS): Antiviral drug candidate
17.2.2021 10:44:00 EET | Business Wire | Press release
A portfolio project of Xlife Sciences AG (XLS) is developing a promising drug candidate against SARS-CoV-2 as well as other flu viruses. The active ingredient inhibits the viral replication and acts against infection related inflammatory processes. It is already in use in humans.
Research & Development is actively looking for Covid-19 therapies around the world. In this way, the aim is to focus on reducing viral replication in early stages and to treat inflammatory effects at a later stage.
The drug candidate developed by the portfolio project company of Xlife Sciences AG has shown that it can offer an alternative therapeutic approach in several phases of the disease, as it both reduces the viral load and inhibits inflammation in the body.
Oliver R. Baumann, CEO of Xlife is delighted about the latest results: "We are very confident that the medical drug can be used in various phases of Covid-19 due to its specific properties and are pleased to contribute to fighting the global pandemic". Baumann added that it can be assumed that the active principle can be transferred to other respiratory viruses as well. This is subject to further research.
According to Xlife, the drug candidate has efficiently reduced the viral load of lung cells infected with influenza in several cell experiments. Tests with SARS-CoV-2 pathogens have also shown a high level of effectiveness. In addition, various inflammatory processes in the body have been effectively combated. The active ingredient is already being used in humans.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
|
Language: |
English |
|
Company: |
Xlife Sciences AG Klausstrasse 19 8008 Zürich Switzerland |
|
Phone: |
0041 44 385 84 60 |
|
E-mail: |
|
|
Internet: |
|
|
ISIN: |
CH0461929603 |
|
WKN: |
A2PK6Z |
|
Listed: |
Regulated Unofficial Market in Frankfurt, Munich |
|
EQS News ID: |
1168858 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006282/en/
Contact information
For media inquiries:
Oliver R. Baumann, CEO Xlife Sciences AG, Tel.+41 44 385 84 60
oliver.baumann@xlifesciences.ch
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 18:22:00 EEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 17:00:00 EEST | Press release
Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks with financing tech embedded directly into sales tools such as Salesforce, enabling 97% of lending applications to be vetted and
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 16:00:00 EEST | Press release
ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527813115/en/ ClickHouse Co-Founders (left to right): Yury Izrailevsky, Aaron Katz, Alexey Milovidov Growth When ClickHouse closed its $400 million Series D in January 2026, it
Wasabi and Liverpool FC Renew Multi-year Partnership to Scale Global Fan Growth27.5.2026 16:00:00 EEST | Press release
Wasabi Technologies, the hot cloud storage company, today announced a multi-year extension of its partnership with Liverpool Football Club (LFC), deepening its role as the club’s Official Cloud Storage Partner. The renewed deal will see Wasabi help power the next phase of LFC’s global content strategy through Wasabi AiR, the intelligent media storage service, enabling the club to move faster, scale smarter, and deliver more personalised fan experiences that bring supporters across the world closer to the club. Together, the partnership empowers LFC to create, store, find, and publish content faster, helping to deliver rapid match and social output and serve its global fanbase with richer, more dynamic storytelling. Meanwhile, LFC serves as a strategic partner in Wasabi’s worldwide expansion, with brand visibility that grows Wasabi’s partner and customer bases in key markets across Europe, Asia, and North America. A strategic global partnership spanning tech, fan engagement, brand marke
Kraken Launches Bitcoin Vault to Make Earning on Bitcoin Easy for Millions of Customers27.5.2026 16:00:00 EEST | Press release
Kraken is launching Bitcoin Vault, a new product within Kraken Earn designed to help customers put their Bitcoin to work in a simple and trusted way. Built for long-term Bitcoin holders, Bitcoin Vault enables customers to earn BTC-denominated rewards while holding Bitcoin. Bitcoin Vault is powered by Veda, with strategy design and risk curation by Sentora. Their platforms are designed to manage risks and allocate the vaults to well-known onchain protocols like Aave, Morpho, Tydro and more. It is designed to make earning on Bitcoin more accessible, whether someone already holds Bitcoin with conviction or is just starting to build a long-term position. For many investors, Bitcoin is an asset they plan to hold forever and Bitcoin Vault is built around that behavior. Instead of introducing more complexity, Kraken offers a more intuitive path: hold Bitcoin, earn rewards in BTC and manage it directly from a Kraken account. “Many Bitcoin holders on Kraken have made it clear they want simple w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom